Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MDH-032 is a microbial extracellular vesicle (EV)-based therapeutic candidate under development by MD Healthcare. It is designed to target inflammatory and fibrotic pathways for the treatment of non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD). MDH-032 utilizes MD Healthcare's proprietary microbial EV platform, which leverages the immunomodulatory and tissue-regenerative properties of commensal bacteria-derived extracellular vesicles to modulate host immune responses and promote tissue repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MDH-032.